Abiopharma

FDA approve MEROPENEM

FDA approve HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm

Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors

Xylo Technologies Ltd (XYLO) was removed from the list of traded instruments on NASDAQ exchange

NASDAQ symbol attribute type Security_Name was changed. Previous value: Xylo Technologies Ltd. - American Depositary Shares. New value: Xylo Technologies Ltd. - American Depositary Shares.

NASDAQ symbol attribute type Test_mode was changed. Previous value: N. New value: Xylo Technologies Ltd. - American Depositary Shares.

NASDAQ symbol attribute type Financial_Status was changed. Previous value: N. New value: Xylo Technologies Ltd. - American Depositary Shares.

SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT

Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)

argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG

[Press Release] HUTCHMED Announces Appointment of Acting Chief Executive Officer

Ceasing to be a substantial holder

Q & M Dental Group (Singapore) Limited - Announcement

PhillipCapital’s Equity Research – Bump in the Road, Scaling Up Journey Intact